FDA Approves AstraZeneca's FluMist, First At-Home Flu Vaccine for Self-Administration

Sep 20, 2024, 06:40 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first influenza vaccine that does not require administration by a healthcare provider. The approval covers individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. FluMist, designed for the prevention of influenza caused by virus subtypes A and B, will be available through third-party pharmacies, where individuals can complete a screening and eligibility assessment when ordering the vaccine.